<DOC>
	<DOCNO>NCT00329225</DOCNO>
	<brief_summary>This 24-week study compare effect add drug rosiglitazone ( 2mg 4mg ) placebo insulin patient Type 2 diabetes mellitus ( non-insulin-dependent ) achieve blood glucose goal use insulin alone . This study require total seven visit 28 week .</brief_summary>
	<brief_title>Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Have Type II diabetes mellitus ( noninsulindependent ) . Females must postmenopausal ( &gt; 12 month without menstrual period ) , surgically sterile , must use oral contraceptive , Norplant , Depoprovera , IUD , diaphragm spermicide condom . Females childbearing potential must use acceptable contraceptive measure least one month prior screen 30 day complete study . Must insulin therapy alone continuously least 8 week prior screen ( minimum dose 30 unit per day ) . Patients take insulin combination single oral antidiabetic agent may oral agent discontinue insulin dose optimize 8 week period prior screen consider good study candidate respect . HbA1c &gt; 7.5 % Prescreen Screen subject discontinue antidiabetic agent prescreening . Provide sign Informed Consent . Females lactate , pregnant , plan become pregnant . Use drug call thiazolidinedione within 6 month prior screen , one oral antidiabetic agent ( include combination agent Glucovance ) combination insulin 3 month prior screen . Use investigational drug blood glucose control within 3 month screen regardless treatment regimen , use investigational agent within 30 day precede study entry . Use niacin ( include dos find multivitamin ) oral corticosteroid within 3 month screen . Patients ongoing swell due fluid accumulation history require treatment drug 12 month prior screen . Patients document history significant hypersensitivity ( e.g. , difficulty swallowing , difficulty breathing , tachycardia skin reaction ) drug call thiazolidinediones similar drug , prior fluid related intolerability thiazolidinediones . Presence clinically significant kidney liver disease . Anemia . Presence unstable severe angina coronary insufficiency . Patients ongoing CHF ( chronic heart failure ) history CHF . Recent history suspicion current drug abuse alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus Thiazolidinediones Insulin</keyword>
</DOC>